Results 111 to 120 of about 275,152 (253)

The Psoriatic Disease Assessment Index (PSODAI) Score to Evaluate Systemic Involvement of Psoriasis

open access: yesPsoriasis: Targets and Therapy
Yanhua Liang,1 Baoqing Deng,2 Epipode Ntawuyamara,3 Hervé Bachelez,4 Fuxi Wang,5 Hao Zhang,6 Zhenying Zhang,7 Zhengfeng Li,7 Lin Dang,8 Yajie Wang,1 Xianbiao Zou,9 Li Wang,10 Dejian Duan,11 Hongxiang Chen,12 Wenjun Zheng,13 Hui Huang,14 Min Zhang,15 ...
Liang Y   +22 more
doaj  

Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim To evaluate the effects of carbamazepine, a strong cytochrome P450 (CYP)3A4 inducer, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader. Methods This was a phase 1, open‐label, fixed‐sequence, two‐period study in healthy adult participants.
Hechuan Wang   +7 more
wiley   +1 more source

A Prospective, Multicenter, Randomized, Assessor-Blinded Study Assessing the Efficacy and Safety of Injectable Non-Cross-Linked Hyaluronic Acid for Improving Facial Skin Rejuvenation

open access: yesClinical, Cosmetic and Investigational Dermatology
Haiyan Cheng,1 Meng Jiang,1 Shan Zhong,1 Xinhai Liu,2 Dongsheng Cao,3 Qiuyuan Feng,4 Yongzhong Li,5 Wei Xu1 1Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing, People’s Republic of China; 2Department of Plastic ...
Cheng H   +7 more
doaj  

Digital diagnostics, biomarkers and therapeutics in an evolving healthcare system: From promise to practice

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Health care is shifting towards a digital‐guided system, integrating digital diagnostics, biomarkers and therapeutics in many care pathways. However, despite rapid technological advancement and preliminary adoption accelerated by the COVID‐19 pandemic, a significant implementation gap persists. This narrative review explores the causes of this
Mees H. P. Stoop   +3 more
wiley   +1 more source

Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control

open access: yesClinical, Cosmetic and Investigational Dermatology
Maoying Li,1 Xi Wang,2 Jiehui Chen,2 Tao Deng,2 Cuihong Lian3 1Department of Dermatology and Venereology,Guanxi University of Chinese Medicine, Nanning, 530000, People’s Republic of China; 2Department of Dermatology and Venereology,The First Clinical ...
Li M, Wang X, Chen J, Deng T, Lian C
doaj  

Increasing the reporting of adverse drug reaction‐related hospitalizations using an ICD‐10‐based identification workflow: A multicentre study from Switzerland

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Background Reporting adverse drug reactions (ADRs) is essential for drug safety. In Switzerland, healthcare professionals are legally required to report serious and unlabelled ADRs, yet under‐reporting remains widespread. We tested a novel method to increase reporting of ADR‐related hospitalizations.
Georgia Anita Weber   +7 more
wiley   +1 more source

Morbihan Disease May Induce Nonspecific Inflammatory of Extra-Facial Region: A Case Report and Literature Review

open access: yesClinical, Cosmetic and Investigational Dermatology
FeiFang Deng,1,2 Peng Wang2 1Women and Children’s Health Care Hospital of Luohu, Shenzhen, People’s Republic of China; 2Department of Dermatology, Affiliated Nanshan Hospital of Shenzhen University (Shenzhen Nanshan People’s Hospital), Shenzhen ...
Deng F, Wang P
doaj  

A Real-world Meta-analysis Study of Disease Severity in European Patients Who Received Baricitinib for Atopic Dermatitis: Data from BioDay, SCRATCH and TREATgermany. [PDF]

open access: yesActa Derm Venereol
Boesjes C   +16 more
europepmc   +1 more source

Advanced therapy medicinal products (ATMPs) – An analysis of the global regulatory status

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Background A rapid progress in the development of advanced therapy medicinal products (ATMPs) has taken place over the past decades. The ATMPs hold great potential but face challenges in the clinical development and the regulatory process.
Allan Cramer   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy